Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh; F. Hooijberg; C. Bastida; A. D.R. Huitema; T. Rispens; C. G. Wolbink

doi:10.55563/CLINEXPRHEUMATOL/XN5I2Y

Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh^*
, F. Hooijberg
, C. Bastida
, A. D.R. Huitema
, T. Rispens
, C. G. Wolbink

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	664-665
Number of pages	2
Journal	Clinical and Experimental Rheumatology
Volume	40
Issue number	3
DOIs	https://doi.org/10.55563/CLINEXPRHEUMATOL/XN5I2Y
Publication status	Published - 2022
Externally published	Yes

Access to Document

10.55563/CLINEXPRHEUMATOL/XN5I2Y

Cite this

@article{9f4bedfc75044509b2ffd8ff9f1512a6,

title = "Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?",

author = "Z. Layegh and F. Hooijberg and C. Bastida and Huitema, \{A. D.R.\} and T. Rispens and Wolbink, \{C. G.\}",

year = "2022",

doi = "10.55563/CLINEXPRHEUMATOL/XN5I2Y",

language = "English",

volume = "40",

pages = "664--665",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",